|
1
|
Rickert CH and Paulus W: Epidemiology of
central nervous system tumors in childhood and adolescence based on
the new WHO classification. Childs Nerv Syst. 17:503–511. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Vogelstein B, Lane D and Levine AJ:
Surfing the p53 network. Nature. 408:307–310. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Phatak P, Selvi SK, Divya T, Hegde AS,
Hegde S and Somasundaram K: Alterations in tumour suppressor gene
p53 in human gliomas from Indian patients. J Biosci. 27:673–678.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Olivier M, Eeles R, Hollstein M, Khan MA,
Harris CC and Hainaut P: The IARC TP53 database: new online
mutation analysis and recommendations to users. Hum Mut.
19:607–614. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Felley-Bosco E, Weston A, Cawley HM,
Bennett WP and Harris CC: Functional studies of a germ-line
polymorphism at codon 47 within the p53 gene. Am J Hum Genet.
53:752–759. 1993.PubMed/NCBI
|
|
6
|
Harris N, Brill E, Shohat O, Prokocimer M,
Wolf D, Arai N and Rotteri V: Molecular basis for heterogeneity of
the human p53 protein. Mol Cell Biol. 6:4650–4656. 1986.PubMed/NCBI
|
|
7
|
Lehman TA, Haffty BG, Carbone CJ, Bishop
LR, Gumbs AA, Krishnan S, Shields PG, Modali R and Turner BC:
Elevated frequency and functional activity of a specific germ-line
p53 intron mutation in familial breast cancer. Cancer Res.
60:1062–1069. 2000.PubMed/NCBI
|
|
8
|
Walker KK and Levine AJ: Identification of
a novel p53 functional domain that is necessary for efficient
growth suppression. Proc Natl Acad Sci. 93:15335–15340. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sakamuro D, Sabbatini P, White E and
Prendergast GC: The polyproline region of p53 is required to
activate apoptosis but not growth arrest. Oncogene. 15:887–898.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Dumont P, Leu JI, Pietra ACD III, George
DL and Murphy M: The codon 72 polymorphic variants of p53 have
markedly different apoptotic potential. Nat Genet. 33:357–365.
2003. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Langerød A, Bukholm IRK, Bregård A,
Lønning PE, Andersen TI, Rognum TO, Meling GI, Lothe RA and
Børresen-Dale AL: The TP53 codon 72 polymorphism may affect the
function of TP53 mutations in breast carcinomas but not in
colorectal carcinomas. Cancer Epidemiol Biomarkers Prev.
11:1684–1688. 2002.PubMed/NCBI
|
|
12
|
Maarten TB, Struyk L, Tjong-A-Hung SP,
Gruis N, Huurne J, Westendorp RGJ, Vermeer BJ, Bavinck JNB and
Schegget J: Cutaneous squamous cell carcinoma and p53 codon 72
polymorphism: a need for screening? Mol Carcinog. 30:56–61. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Granja F, Moraria J, Moraria EC, Correa
LAC, Assumpcao LVM and Ward LS: Proline homozygosity in codon 72 of
p53 is a factor of susceptibility for thyroid cancer. Cancer Lett.
210:151–157. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tiwawech D, Srivatankul P, et al: The p53
codon 72 polymorphism in Thai nasopharyngeal carcinoma. Cancer
Lett. 198:69–75. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
El Hallani S, Ducray F, Idbaih A, Marie Y,
Boisselier B, Colin C, Laigle-Donadey F, Rodero M, Chinot O,
Thillet J, Hoang-Xuan K, Delattre JY and Sanson M: TP53 codon 72
polymorphism is associated with age at onset of glioblastoma.
Neurology. 72:332–336. 2009.PubMed/NCBI
|
|
16
|
Idbaih A, Boisseliera B, Marie Y, Sanson
M, El Hallani S, Crinière E, Fourtassi M, Paris S, Carpentier C,
Rousseau A, et al: Influence of MDM2 SNP309 alone or in combination
with the TP53 R72P polymorphism in oligodendroglial tumors. Brain
Res. 1198:16–20. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Malmer BS, Feychting M, Lönn S, Lindström
S, Grönberg H, Ahlbom A, Schwartzbaum J, Auvinen A,
Collatz-Christensen H, Johansen C, Kiuru A, Mudie N, Salminen T,
Schoemaker MJ, Swerdlow AJ and Henriksson R: Genetic variation in
p53 and ATM haplotypes and risk of glioma and meningioma. J
Neurooncol. 82:229–237. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pinto GR, Yoshioka FKN, Silva RLL, Clara
CA, Santos MJ, Almeida JRW, Burbano RR, Rey JA and Casartelli C:
Prognostic value of TP53 Pro47Ser and Arg72Pro single nucleotide
polymorphisms and the susceptibility to gliomas in individuals from
Southeast Brazil. Genet Mol Res. 7:207–216. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Rajaraman P, Wang SS, Rothman N, Brown MM,
Black PM, Fine HA, Loeffler JS, Selker RG, Shapiro WR, Chanock SJ
and Inskip PD: Polymorphisms in apoptosis and cell cycle control
genes and risk of brain tumors in adults. Cancer Epidemiol
Biomarkers Prev. 16:1655–1661. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Parhar P, Ezer R, Shao Y, Allen J, Miller
D and Newcomb E: Possible association of p53 codon 72 polymorphism
with susceptibility to adult and pediatric high-grade astrocytomas.
Mol Brain Res. 137:98–103. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lima-Ramos Vt, Pacheco-Figueiredo L, Costa
S, Pardal F, Silva A, Amorim J, Lopes JM and Reis RM: TP53 codon 72
polymorphism in susceptibility, overall survival, and adjuvant
therapy response of gliomas. Cancer Genet Cytogenet. 180:14–19.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zintzaras E and Ioannidis JP:
Heterogeneity testing in metaanalysis of genome searches. Genet
Epidemiol. 28:123–137. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Higgins JP and Thompson SG: Quantifying
heterogeneity in a meta-analysis. Stat Med. 21:1539–1558. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lau J, Ioannidis JP and Schmid CH:
Quantitative synthesis in systematic reviews. Ann Intern Med.
127:820–826. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tobias A: Assessing the influence of a
single study in the meta-analysis estimate. Stata Tech Bull.
8:15–17. 1999.
|
|
26
|
Begg C and Mazumdar M: Operating
characteristics of a rank correlation test for publication bias.
Biometrics. 50:1088–1101. 1994. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Egger M, Smith GD, Schneider M and Minder
C: Bias in meta-analysis detected by a simple, graphical test. BMJ.
315:629–634. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Idbaiha A, Boisselier B, Sanson M,
Criniere E, Livad S, Marie Y, Carpentier C, Paris S, Laigle-Donadey
F, Mokhtari K, Kujas M, Hoang-Xuan K, Delattre O and Delattre J-Y:
Tumor genomic profiling and TP53 germline mutation analysis of
first-degree relative familial gliomas. Cancer Genet Cytogenet.
176:121–126. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Malmer B, Gronberg H, Andersson U, Jonsson
BA and Henriksson R: Microsatellite instability, PTEN and p53
germline mutations in glioma families. Acta Oncologica. 40:633–637.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Malmer B, Feychting M, Lonn S, Ahlbom A
and Henriksson R: p53 Genotypes and risk of glioma and meningioma.
Cancer Epidemiol Biomarkers Prev. 14:2220–2223. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Portwine C, Chilton-MacNeill S, Brown C,
Sexsmith E, McLaughlin J and Malkin D: Absence of germline and
somatic p53 alterations in children with sporadic brain tumors. J
Neurooncol. 52:227–235. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zawlik I, Kita D, Vaccarella S,
Mittelbronn M, Franceschi S and Ohgaki H: Common polymorphisms in
the MDM2 and TP53 genes and the relationship between TP53 mutations
and patient outcomes in glioblastomas. Brain Pathol. 19:188–194.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Aka K, Bruner JM, Bondy ML, Ligon K, Nishi
K, Giglio AD, Moser RR, Levin VA and Saya H: Detection of p53
alterations in human astrocytomas using frozen tissue sections for
the polymerase chain reaction. J Neuro Oncol. 16:125–133. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chang ZN, Guo CL, Ahronowitz I,
Stemmer-Rachamimov RO, MacCollin M and Nunes FP: A role for the p53
pathway in the pathology of meningiomas with NF2 loss. J
Neurooncol. 91:265–270. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Paunu N, Syrjakoski K, Sankila R, Simola
KOJ, Helen P, Niemela M, Matikainen M, Isola J and Haapasalo H:
Analysis of p53 tumor suppressor gene in families with multiple
glioma patients. J Neurooncol. 55:159–165. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ohgaki H, Dessen P, Jourde B, Horstmann S,
Nishikawa T, Patre PLD, Burkhard C, Schuler D, Probst-Hensch NM,
Maiorka PC, et al: Genetic pathways to glioblastoma: a
population-based study. Cancer Res. 64:6892–6899. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Uno M, Oba-Shinjo SM, Wakamatsu A, Huang
N, Avancini Ferreira Alves V, Rosemberg S, Pires de Aguiar PH,
Leite C, Miura F, Marino Junior R, Scaff M and Nagahashi-Marie SK:
Association of TP53 mutation, p53 overexpression, and p53 codon 72
polymorphism with susceptibility to apoptosis in adult patients
with diffuse astrocytomas. Int J Biol Markers. 21:50–57.
2006.PubMed/NCBI
|
|
38
|
Almeida LO, Custódio AC, Pinto GR, Santos
MJ, Almeida JRW, Clara CA, Rey JA and Casartelli C: Polymorphisms
and DNA methylation of gene TP53 associated with extra-axial brain
tumors. Genet Mol Res. 8:8–18. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Jha P, Jha P, Pathak P, Chosdol K, Suri V,
Sharma MC, Kumar G, Singh M, Mahapatra AK and Chitra S: TP53
polymorphisms in gliomas from Indian patients: Study of codon 72
genotype, rs1642785, rs1800370 and 16 base pair insertion in
intron-3. Exp Mol Pathol. 90:167–172. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Biros E, Kalina I, Kohut A, Bogyiova E,
Alagovic J and Ulla I: Allelic and haplotype frequencies of the p53
polymorphisms in brain tumor patients. Physiol Res. 51:59–64.
2002.PubMed/NCBI
|
|
41
|
Idbaih A, Boisselier B, Mariea Y, El
Hallani S, Sanson M, Criniere E, Rodero M, Carpentier C, Paris S,
Laigle-Donadey F, Ducray F, Hoang-Xuan K and Delattre JY: TP53
codon 72 polymorphism, p53 expression, and 1p/19q status in
oligodendroglial tumors. Cancer Genet Cytogenet. 177:103–107. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Wang LE: Polymorphisms of DNA repair genes
and risk of glioma. Cancer Res. 64:5560–5563. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Network TCGAR. Comprehensive genomic
characterization defines human glioblastoma genes and core
pathways. Nature. 455:1061–1068. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Sjalander A, Birgander R, Saha N, Beckman
L and Beckman G: p53 polymorphisms and haplotypes show distinct
diff erences between major ethnic groups. Hum Hered. 46:41–48.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Kashima T, Makino K, Soemantri A and
Ishida T: TP53 codon 72 polymorphism in 12 populations of insular
southeast Asia and Oceania. J Hum Genet. 52:694–697. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Thomas M, Kalita A, Labrecque S, Pim D,
Banks L and Matlashwski G: Two polymorphic variants of wild-type
p53 differ biochemically and biologically. Mol Cell Biol.
19:1092–1100. 1999.PubMed/NCBI
|
|
47
|
Francisco G, Menezes PR, Eluf-Neto J and
Chammas R: Arg72Pro TP53 polymorphism and cancer susceptibility: A
comprehensive meta-analysis of 302 case-control studies. Int J
Cancer. 129:920–30. 2011. View Article : Google Scholar : PubMed/NCBI
|
